PMID- 2373872
OWN - NLM
STAT- MEDLINE
DCOM- 19900827
LR  - 20211203
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 162
IP  - 2
DP  - 1990 Aug
TI  - Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis 
      factor-alpha in experimental gram-negative shock.
PG  - 421-7
AB  - A monoclonal antibody to recombinant murine tumor necrosis factor-alpha (TNF 
      alpha), TN3-19.12, was used to explore pathogenetic mechanisms and therapeutic 
      strategies in gram-negative shock. In mice receiving an LD90 dose of Escherichia 
      coli O111, TN3-19.12 prevented death if given 1.5 h before or 30 min after 
      challenge. Less protection was conferred if the antibody was given 2.5 h after 
      challenge. In control mice receiving an irrelevant antibody, L2-3D9, TNF alpha 
      levels rose (less than or equal to 185.1 +/- 26.1 ng/ml) by 90 min and had 
      returned to baseline by 5 h. Mice receiving TN3-19.12 did not have this response. 
      TN3-19.12 was of limited benefit in mice receiving Pseudomonas aeruginosa but had 
      no protective effect in cyclophosphamide-treated mice receiving Klebsiella 
      pneumoniae. In L2-3D9-treated mice, TNF alpha levels were elevated to 61.8 +/- 
      27.9 and 49.7 +/- 5.1 ng/ml by 90 min in the two models, respectively. TNF alpha 
      levels in TN3-19.12-treated mice in these two models were very low (3.9-5.5 
      ng/ml). TNF alpha is a mediator in gram-negative shock; antibody to TNF alpha can 
      be of value in prophylaxis and treatment, but its clinical use remains to be 
      established.
FAU - Silva, A T
AU  - Silva AT
AD  - Department of Bacteriology, Royal Postgraduate Medical School, Hammersmith 
      Hospital, London, United Kingdom.
FAU - Bayston, K F
AU  - Bayston KF
FAU - Cohen, J
AU  - Cohen J
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Colony Count, Microbial
MH  - Disease Models, Animal
MH  - Enterobacteriaceae Infections/complications
MH  - Gram-Negative Bacteria
MH  - *Immunization, Passive
MH  - Immunosuppression Therapy
MH  - Male
MH  - Mice
MH  - Pseudomonas Infections/complications
MH  - Sepsis/*complications
MH  - Shock, Septic/*prevention & control/therapy
MH  - Tumor Necrosis Factor-alpha/analysis/*immunology
MH  - Weight Loss
EDAT- 1990/08/01 00:00
MHDA- 1990/08/01 00:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 1990/08/01 00:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
AID - 10.1093/infdis/162.2.421 [doi]
PST - ppublish
SO  - J Infect Dis. 1990 Aug;162(2):421-7. doi: 10.1093/infdis/162.2.421.